ENTtoday
  • Home
  • COVID-19
  • Practice Focus
    • Allergy
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Departments
    • Issue Archive
    • TRIO Best Practices
      • Allergy
      • Facial Plastic/Reconstructive
      • Head and Neck
      • Laryngology
      • Otology/Neurotology
      • Pediatric
      • Rhinology
      • Sleep Medicine
    • Career Development
    • Case of the Month
    • Everyday Ethics
    • Health Policy
    • Legal Matters
    • Letter From the Editor
    • Medical Education
    • Online Exclusives
    • Practice Management
    • Resident Focus
    • Rx: Wellness
    • Special Reports
    • Tech Talk
    • Viewpoint
    • What’s Your O.R. Playlist?
  • Literature Reviews
    • Allergy
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Events
    • Featured Events
    • TRIO Meetings
  • Contact Us
    • About Us
    • Editorial Board
    • Triological Society
    • Advertising Staff
    • Subscribe
  • Advertise
    • Place an Ad
    • Classifieds
    • Rate Card
  • Search

Otolaryngologists See Immunotherapy as Hope for Patients with Head and Neck Cancer

by Nikki Kean • February 6, 2020

  • Tweet
  • Email
Print-Friendly Version

Harnessing the power of the immune system to fight advanced head and neck cancers topped the list of breakthroughs for several otolaryngologists who were asked to identify recent research that has transformed clinical care.

You Might Also Like

  • New Immunotherapy Improves Survival Rates in Squamous Cell Carcinoma of the Head and Neck
  • A Look at Immunotherapy’s Potential for Head and Neck Cancer Treatment
  • New Research Calls for Sex-Specific Therapies for Thyroid, Head and Neck Cancer
  • Experts Discuss HPV-Positive Head and Neck Cancer
Explore This Issue
February 2020

But that excitement is a relatively new development for the profession. Indeed, for many years, otolaryngologists could not be blamed for feeling like they’d been left on the sidelines while immune checkpoint inhibitors and other immunotherapies scored victories against a wide range of malignancies.

“Think about it: For years, cisplatin had been our primary chemotherapy drug for head and neck cancers, even though it was first approved in 1978,” said Jennifer R. Grandis, MD, professor of otolaryngology–head and neck surgery at the University of California, San Francisco. “And while cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, was approved in 2006, after 13 years of clinical use, it’s been a bit of a disappointment in terms of achieving any major gains in survival.”

© Science Photo Library / offset

© Science Photo Library / offset

That’s why the more recent approvals of pembrolizumab and nivolumab are such a promising development for patients with advanced head and neck squamous cell carcinoma (HNSCC), Dr. Grandis told ENTtoday. “It now gives the multidisciplinary team of medical oncologists, radiation oncologists, and head and neck surgeons two new tools for augmenting the immune system to target the cancer, rather than having to rely on more highly toxic regimens.”

The efficacy of pembrolizumab (Keytruda, Merck Sharp and Dohme Corp.), a programmed death receptor-1 (PD-1) inhibitor, is a case in point, as evidenced in the KEYNOTE-048 trial that led to the drug’s full approval for HNSCC in 2019 (ClinicalTrials.gov Identifier: NCT02358031). The median overall survival (OS) was 13.0 months for the pembrolizumab plus chemotherapy arm and 10.7 months for the cetuximab plus chemotherapy arm (hazard ratio [HR] 0.77; 95% confidence interval [CI]: 0.63, 0.93; P=0.0067), according to a U.S. Food & Drug Administration press release announcing the approval. In a subgroup of patients with high PD-L1 expression, the OS difference was a bit more pronounced: 14.9 months for the pembrolizumab arm versus 10.7 months for the cetuximab plus chemotherapy arm (HR, 0.61; 95% CI, 0.45-0.83; P=0.0015), according to the FDA.

The benefits of nivolumab (Opdivo, Bristol-Myers Squibb) tell a similar story. Approved in 2016 for patients with HNSCC that has progressed or metastasized after platinum-based chemotherapy, the drug has achieved some of its most impressive OS gains in the CheckMate 141 trial (Oral Oncol 2018;81:45-51). The drug “nearly tripled” OS rates at a minimum of 24 months (16.9%) versus standard therapy (6.0%), first author Robert L. Ferris, MD, PhD, the director of the University of Pittsburgh Medical Center Hillman Cancer Center, told ENTtoday.

Pages: 1 2 3 4 5 | Single Page

Filed Under: Features Tagged With: clinical care, head and neck cancerIssue: February 2020

You Might Also Like:

  • New Immunotherapy Improves Survival Rates in Squamous Cell Carcinoma of the Head and Neck
  • A Look at Immunotherapy’s Potential for Head and Neck Cancer Treatment
  • New Research Calls for Sex-Specific Therapies for Thyroid, Head and Neck Cancer
  • Experts Discuss HPV-Positive Head and Neck Cancer

The Triological SocietyENTtoday is a publication of The Triological Society.

The Laryngoscope
Ensure you have all the latest research at your fingertips; Subscribe to The Laryngoscope today!

Laryngoscope Investigative Otolaryngology
Open access journal in otolaryngology – head and neck surgery is currently accepting submissions.

Classifieds

View the classified ads »

TRIO Best Practices

View the TRIO Best Practices »

Top Articles for Residents

  • Do Training Programs Give Otolaryngology Residents the Necessary Tools to Do Productive Research?
  • Why More MDs, Medical Residents Are Choosing to Pursue Additional Academic Degrees
  • What Physicians Need to Know about Investing Before Hiring a Financial Advisor
  • Tips to Help You Regain Your Sense of Self
  • Should USMLE Step 1 Change from Numeric Score to Pass/Fail?
  • Popular this Week
  • Most Popular
  • Most Recent
    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment
    • Vertigo in the Elderly: What Does It Mean?
    • Experts Delve into Treatment Options for Laryngopharyngeal Reflux
    • Otolaryngologists Have a Major Role to Play in Treating COVID-19 Long-Haulers
    • Some Laryngopharyngeal Reflux Resists PPI Treatment
    • Vertigo in the Elderly: What Does It Mean?
    • New Developments in the Management of Eustachian Tube Dysfunction
    • Some Laryngopharyngeal Reflux Resists PPI Treatment
    • Eustachian Tuboplasty: A Potential New Option for Chronic Tube Dysfunction and Patulous Disease
    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment
    • Podcasts Becoming More Popular Method of Education for Otolaryngologists
    • How to Embrace Optimism in the Midst of the COVID-19 Pandemic
    • Tips on How to Approach Conversations with Patients about the COVID-19 Vaccine
    • Steps You Should Take to Protect Your Voice and Hearing During Telemedicine Sessions
    • Routine Postoperative Adjunct Treatments Unnecessary for Idiopathic Cerebrospinal Fluid Leaks

Polls

Have you spoken with your patients about receiving the COVID-19 vaccine?

View Results

Loading ... Loading ...
  • Polls Archive
  • Home
  • Contact Us
  • Advertise
  • Privacy Policy
  • Terms of Use

Visit: The Triological Society • The Laryngoscope • Laryngoscope Investigative Otolaryngology

Wiley
© 2021 The Triological Society. All Rights Reserved.
ISSN 1559-4939

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.